Cetera Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Cetera Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,100	Closed	-$160K	–	1412
2021 Q2	$160K	Buy	+14,100	New	+$170K	﹤0.01%	1266

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Cetera Advisors's ALDX Position: Q3 2021 in Review

Cetera Advisors sold out of Aldeyra Therapeutics (ALDX) in Q3 2021, closing a stake of 14,100 shares — an estimated $160K sold.

Cetera Advisors first reported a position in ALDX in Q2 2021 and held it in 1 quarter. The position peaked at $160K in Q2 2021. 117 funds tracked by Wall St. Rank hold ALDX as of Q3 2021.

Cetera Advisors reported no remaining Aldeyra Therapeutics position as of Q3 2021 after selling out during the quarter.
Cetera Advisors sold 14,100 Aldeyra Therapeutics shares in Q3 2021, an estimated $160K.
Cetera Advisors first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 1 quarter.
Cetera Advisors's Aldeyra Therapeutics position peaked at $160K in Q2 2021.
117 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2021.

Based on Cetera Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.